Search This Blog

Monday, May 4, 2026

Clene to seek accelerated approval for ALS drug

 

Clene to seek accelerated approval for ALS drug CNM-Au8 with NDA filing planned in Q3 2026 after positive FDA Type C meeting

  • FDA indicated proposed NfL biomarker data may be sufficient to support Clene's accelerated-approval NDA submission.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)